Spur Therapeutics announces positive FDA meeting for FLT201, their gene therapy aimed at treating Gaucher disease.
Spur Therapeutics announces positive FDA meeting for FLT201, their gene therapy aimed at treating Gaucher disease.
02/03/25, 1:14 PM
Location
londonIndustry
biopharma
therapeutics
biotechnology
health care
Spur Therapeutics received favorable feedback from the FDA regarding their Phase 3 trial plans for FLT201, a gene therapy for Gaucher disease. The company aims to start dosing in the second half of 2025, with potential accelerated approval based on early data.
Company Info
Location
london, england, united kingdom
Additional Info
Spur Therapeutics is a biopharmaceutical company focused on developing innovative gene therapies. Their lead candidate, FLT201, targets Gaucher disease type 1 using an adeno-associated virus (AAV) approach. The company aims to offer a transformative one-time therapy for patients, aiming to reduce the treatment burden associated with the disease. Spur is committed to advancing its therapies through rigorous clinical trials and regulatory engagement.